
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Three new studies examine research on biomarkers to predict lifetime risk of Alzheimer disease; diet and brain tissue volume; and cognitive impairment in active older adults.



